Omeros (OMER) Cash from Financing Activities (2010 - 2026)
Omeros' (OMER) quarterly Cash from Financing Activities came in at -$22.0 million in Q1 2026, down 1095.32% year-on-year from $2.2 million in Q1 2025, and up 65.89% quarter-over-quarter from -$64.4 million in Q4 2025.
Omeros (OMER) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Omeros has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$22.0 million for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$22.0 million, down 1095.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$62.3 million (down 66.66% YoY), and the FY2025 annual result was -$42.2 million, down 167.06% from the prior year.
- Cash from Financing Activities came in at -$22.0 million for Q1 2026 at Omeros, up from -$64.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $124.8 million in Q3 2022 to a low of -$105.0 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is -$651000.0 (2022), against an average of $993764.7.
- Across the five-year window, Cash from Financing Activities jumped 26016.53% in 2022 and slumped 16021.81% in 2023, its largest moves.
- Omeros' Cash from Financing Activities stood at -$651000.0 in 2022, then plunged by 16021.81% to -$105.0 million in 2023, then jumped by 96.1% to -$4.1 million in 2024, then tumbled by 1473.6% to -$64.4 million in 2025, then jumped by 65.89% to -$22.0 million in 2026.
- The last three Cash from Financing Activities figures came in at -$22.0 million (Q1 2026), -$64.4 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 85,464.43 |
| 10 | Omeros | 628.56 Mn | 493.24 Mn | 9.31 Mn | -21.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.98 Mn |
| Mar 31, 2026 | -21.98 Mn |
| Dec 31, 2025 | -64.44 Mn |
| Dec 31, 2025 | -64.44 Mn |
| Sep 30, 2025 | 25.83 Mn |
| Sep 30, 2025 | 25.83 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Mar 31, 2025 | -1.84 Mn |
| Mar 31, 2025 | -1.84 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Sep 30, 2024 | -4.58 Mn |
| Sep 30, 2024 | -4.58 Mn |
| Jun 30, 2024 | -26.88 Mn |
| Jun 30, 2024 | -26.88 Mn |
| Mar 31, 2024 | 98.43 Mn |
| Mar 31, 2024 | 98.43 Mn |
| Dec 31, 2023 | -104.95 Mn |
| Dec 31, 2023 | -104.95 Mn |